The Korean Journal of Food And Nutrition (한국식품영양학회지)

The Korean Society of Food and Nutrition (한국식품영양학회)
권호 표지

Immunostimulating Activity of Beta-Glucan Isolated from the Cell Wall of Mutant Saccharomyces cerevisiae, and Its Anti-Tumor Application in Combination with Cisplatin

Saccharomyces cerevisiae 변이주 세포벽 유래의 베타글루칸의 면역활성 및 Cisplatin과의 병용에 의한 항암 상승작용

  • 김완재 (건국대학교 의료생명대학 생명공학과) ;
  • 윤택준 (유한대학 식품영양과) ;
  • 김동우 ((주)네추럴에프엔피) ;
  • 문원국 ((주)네추럴에프엔피) ;
  • 이광호 (건국대학교 의료생명대학 생명공학과)
  • Received : 2010.01.24
  • Accepted : 2010.04.05
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cisplatin(cis-diamminedichloroplatium) is one of the most effective anti-cancer drugs being clinically used in the treatment of solid tumors. Despite its therapeutic benefits, its use in clinical practice is often limited because of dose related toxicity. It is known that yeast cell wall beta-glucans possess immuno-modulating properties, which allows for their application in antitumor therapy. IS2 is a kind of beta-glucan derived from the cell wall of mutated Saccharomyces cerevisiae, which exhibits anti-cancer activity in vitro and in vivo. The present study explored the possibility of combination therapy of IS2 with cisplatin. In experimental metastasis of colon26-M3.1 cells, prophylactic intravenous administration of IS-2 in combination with cisplatin effectively inhibited tumor metastasis compared with cisplatin alone or IS-2 treatment in vivo. IS-2 effectively enhanced Th1 type cytokines including IFN-$\gamma$, IL-2, IL-12 and GM-CSF. Simultaneously, this combined treatment inhibited production of Th2 type cytokines compared with control. These results suggested that IS-2 can be applied in combination therapy with anti-cancer drugs to minimize their side effects.

Keywords

References

  1. Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, Straten P. 2003. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13:449-459 https://doi.org/10.1016/j.semcancer.2003.09.009
  2. Carlton BC, Brown BJ, Gene mutation. 1981. Manual of Methods for General Bacteriology. pp.222-242. American Society for Microbiology
  3. Chan GCF, Chan WK, Sze DMY. 2009. The effect of ${\beta}-glucan$ on human immune and cancer cells. J Hematol Oncol 2:1-11 https://doi.org/10.1186/1756-8722-2-1
  4. Dauphinee MJ, Kipper SB, Wofsy D, Talal N. 1981. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 127:2483-2487
  5. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. 1991. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451
  6. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M, Ueyama Y. 2000. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11:815-819 https://doi.org/10.1023/A:1008375208574
  7. Jeong JH, Lee JM, Lee CH, Cho JH, Jang JB, Lee KS. 2009. Anti-tumor metastatic effect and activation of innate immunity by extracy of Mori radicis cortex. J Orient Obstet Gynecol 22:31-40
  8. Kelly G, Edmund G. 2001. Process for glucan preparation and therapeutic uses of glucan. US Patent 6,242,594
  9. Kim DG, Kim Kj, Ju SM, Kim YI, Choi HS, Keum KS, Kim WS, Gao YA, Jeon BH. 2003. Protective effect of Ganopoly and Ganopoly/C+ on nephrotoxicity induced by cisplatin in rat. Korean J Orient Physiol Pathol 17:316-325
  10. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW. 2009. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer in press
  11. Kogan G, Pajtinka M, Babincova M, Miadokova E, Rauko P, Slamenova D, Korolenko TA. 2008. Yeast cell wall polysaccharides as antioxidants and antimutagens: Can they fight cancer? Neoplasma 55:387-393
  12. Kovacs E. 2000. Serum level IL-12 and the production of IFNgamma, IL-2 and IL-4 by peripheral blood mononuclear cell (PBMC) in cancer patients treated with Ciscum albun extract. Biomed Pharmacother 54:305-310 https://doi.org/10.1016/S0753-3322(00)80052-9
  13. Lasek W, Feleszko W, Golab J, Stokłosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M. 1997. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 2:100-108
  14. Lin WW, Karin M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183 https://doi.org/10.1172/JCI31537
  15. Liu J, Gunn L, Hansen R, Yan J. 2009. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol 86:208-214 https://doi.org/10.1016/j.yexmp.2009.01.006
  16. Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H. 2009. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 9:620-626 https://doi.org/10.1016/j.intimp.2009.02.005
  17. Park JH, Kang MS, Kim HI, Chung BH, Lee KH, Moon WK. 2003. Study on immuno-stimulating activity of ${\beta}-glucan$ isolated from the cell wall of yeast mutant Saccharomyces cerevisiae IS2. Korean J Food Sci Technol 35:483-492
  18. Romagnani S. 1991. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 21:152-158
  19. Song HS, Moon KY. 2006 In vitro antioxidant activity profiles of ${\beta}-glucan$ isolated from yeast Saccharomayces cerevisiae and mutant Saccharomayces cerevisiae IS2. Food Sci Biotechnol 15:437-440
  20. Tohamy AA, El-Ghor AA, El-Nahas SM, Noshy MM. 2003. Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mutat Res 10:45-53
  21. Tsang RY, Al-Fayea T, Au HJ. 2009. Cisplatin overdose: toxicities and management. Drug Saf 32:1109-1122 https://doi.org/10.2165/11316640-000000000-00000
  22. Urosevic M, Dummer R. 2003. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 13:337-342 https://doi.org/10.1016/S1044-579X(03)00024-5
  23. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK. 1997. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70:699-705 https://doi.org/10.1002/(SICI)1097-0215(19970317)70:6<699::AID-IJC12>3.0.CO;2-5
  24. Westermann J, Reich G, Kopp J, Haus U, Dorken B, Pezzutto A. 2001 Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 49:613-620 https://doi.org/10.1007/s002620000159
  25. Yao D, Zhang X, Wei H, Tian Z. 2005. Antisense-induced blockade of GATA-3 expression could inhibit Th2 excursion of tumor cells in vitro and in vivo. Cell Mol Immunol 2:189-196
  26. Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH. 2008. Anti-tumor metastatic activity of ${\beta}-glucan$ purified from mutated Saccharomyces cerevisiae. Int immunopharmacol 8:36-42 https://doi.org/10.1016/j.intimp.2007.10.005